Certain states in the US have enacted or are actively considering legislation to create PDABs, Prescription Drug Affordability Boards. PDABs are independent state bodies comprised of experts in healthcare and economics, empowered to analyze drug costs and suggest ways to lower state and/or consumer spending, with recommendations applying to some or all individuals within a state.
CRA’s Life Sciences experts Rhett Johnson and Kira Gordon examine how PDABs could influence states’ spending on prescription drugs and the potential impact on the pharmaceutical industry.
Click here to read more about the potential and limits of PDABs.
